- BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C
-
The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
- -
-
-
- HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS
-
Heteroaryloxycarbocyclyl compounds of formula (I), and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive -compulsive disorder, and the like. Formula (I)
- -
-
-
- AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS
-
The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
- -
-
Page/Page column 41
(2009/09/28)
-
- NOVEL INTERMEDIATES AND THEIR USE
-
The invention is directed to novel acyloxy imidazole intermediates useful for making certain C- 14 oxycarbonyl carbamate pleuromutilin derivatives. The invention is further directed to a process for making such acyloxy imidazole intermediates and to a pro
- -
-
Page/Page column 16-17
(2010/11/27)
-
- NEW PLEUROMUTILIN DERIVATIVE AND ITS USE
-
The invention is directed to the L-tartrate salt of trans-3-aminocyclobutyl (lS,2R,3S,4S:,6R,7R,8R-,14R)-4-ethenyl-3-hydroxy-2,4,7, 14-tetramethyl-9- oxotricyclo[5.4.3.01,8]tetradec-6-yl imidodicarbonate (Compound IA.) Compound IA is useful for the treatment of a variety of diseases and conditions, such as respiratory tract and skin and skin structure infections. Accordingly, the invention is further directed to pharmaceutical compositions comprising Compound IA. The invention is still further directed to methods of treating respiratory tract and skin and skin structure infections using Compound IA or a pharmaceutical composition comprising Compound IA.
- -
-
Page/Page column 11-12
(2010/11/27)
-